Brief: Sage Therapeutics And Biogen Announce Topline Results From Phase 2 Kinetic 2 Study Of SAGE-324 (BIIB124) For The Treatment Of Essential Tremor

Sage Therapeutics

24/07/2024 11:45

July 24 (Reuters) - Sage Therapeutics  SAGE.O  
    * SAGE THERAPEUTICS AND BIOGEN ANNOUNCE TOPLINE RESULTS FROM
PHASE
2 KINETIC 2 STUDY OF SAGE-324 (BIIB124) FOR THE TREATMENT OF
ESSENTIAL TREMOR
    * SAGE THERAPEUTICS AND BIOGEN ANNOUNCE TOPLINE RESULTS FROM
PHASE
2 KINETIC 2 STUDY OF SAGE-324 (BIIB124) FOR THE TREATMENT OF
ESSENTIAL TREMOR
    * BIOGEN INC - SAGE-324 DID NOT SHOW SIGNIFICANT
DOSE-RESPONSE
    * SAGE THERAPEUTICS INC: SAGE-324 (BIIB124) DID NOT
DEMONSTRATE A
STATISTICALLY SIGNIFICANT DOSE-RESPONSE RELATIONSHIP ON PRIMARY
ENDPOINT
    * BIOGEN INC - SAGE AND BIOGEN TO CLOSE ONGOING SAGE-324
STUDY
    * SAGE THERAPEUTICS INC: DO NOT PLAN TO CONDUCT FURTHER
CLINICAL
DEVELOPMENT OF SAGE-324 IN ET

Source text for Eikon:  ID:nBw9knmm0a 
Further company coverage:  SAGE.O 

 ((Reuters.Briefs@thomsonreuters.com;))